Company Overview
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Dec 2025 Revenue of $241.00K (+7.1% YoY); net profit $-23.76M.
- Trailing 12 Months Year-on-year growth — revenue -34.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.56% |
| 1 Year: | -34.60% |
Stock Price Performance
| 1 Year: | -51.95% |
| 6 Months: | +4.73% |
| 3 Months: | +7.91% |
| 1 Month: | +5.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 55.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COCH Envoy Medical, Inc. PHARMA | 0.71 | -0.93 | $54.81M | 0.00% | - | - | 0.56% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 57.00K | 78.00K | 63.00K | 80.00K | 59.00K | 68.00K | 56.00K | 46.00K | 78.00K | 42.00K | 39.00K | 51.00K |
| Operating Income | -966.28K | -1.07M | -2.99M | -1.49M | -901.36K | -1.80M | -3.77M | -4.48M | -3.38M | -4.88M | -4.85M | -4.97M | -5.11M | -5.07M | -5.71M | -5.96M | -5.57M |
| Net Income | -1.47M | 371.14K | 5.57M | -1.87M | -1.24M | -1.34M | -13.25M | -13.34M | 1.56M | -6.27M | -3.95M | -5.96M | -5.00M | -5.69M | -6.48M | -4.35M | -5.98M |
| Diluted EPS | - | - | - | - | - | -0.13 | -1.31 | -1.31 | 0.13 | -0.41 | -0.29 | -0.39 | -0.29 | -0.32 | -0.35 | -0.08 | -0.07 |
| R&D Expense | - | - | - | - | - | 935.00K | 1.93M | 2.15M | 1.85M | 2.36M | 2.59M | 2.76M | 2.75M | 2.48M | 2.70M | 3.64M | 3.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 237.00K | 316.00K | 225.00K | 241.00K |
| Operating Income | -5.20M | -8.71M | -18.36M | -19.26M | -22.27M |
| Net Income | -251.63K | -15.92M | -29.92M | -20.80M | -23.76M |
| Diluted EPS | - | -1.57 | -2.54 | -1.49 | -1.23 |
| R&D Expense | - | 4.97M | 8.96M | 10.18M | 12.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 119.99K | 426.90M | 2.56M | 8.27M | 11.54M | 8.56M |
| Total Equity | 24.30K | -44.96M | -36.20M | -1.78M | -18.84M | -12.16M |
| Cash & Equivalents | 25.00K | 149.84K | 183.00K | 4.22M | - | - |
| Total Liabilities | 95.69K | 38.62M | 38.75M | 10.05M | 30.38M | 20.32M |
| Current Liabilities | 95.69K | 2.68M | 2.52M | 7.29M | 7.54M | 11.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.80M | -17.09M | -17.95M | -18.20M |
| Investing Cash Flow | - | -218.00K | -153.00K | -980.00K | -179.00K |
| Financing Cash Flow | - | 8.09M | 21.28M | 20.20M | 16.63M |
| Capital Expenditure | - | -218.00K | -153.00K | -980.00K | -179.00K |
| Free Cash Flow | - | -9.02M | -17.24M | -18.93M | -18.38M |
| Net Change in Cash | - | -931.00K | 4.04M | 1.27M | -1.75M |
| Dividends Paid | - | - | - | 2.45M | 1.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -3,673.4% | -5,809.8% | -8,558.2% | -9,240.7% |
| Net Margin % | - | -6,718.6% | -9,469.0% | -9,242.2% | -9,857.3% |
| ROE % | 0.6% | 44.0% | 1,684.8% | 110.4% | 195.4% |
| ROCE % | -1.2% | -23,529.7% | -1,862.0% | -481.4% | 741.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 9.88% | 7.65M | $5.46M |
| 2 | Bleichroeder LP | 8.08% | 6.25M | $4.46M |
| 3 | Vanguard Capital Management LLC | 1.14% | 880.21K | $628.38K |
| 4 | Dsg Capital Advisors, LLC | 0.81% | 625.00K | $446.19K |
| 5 | Geode Capital Management, LLC | 0.70% | 541.73K | $386.74K |
| 6 | Focus Partners Wealth | 0.55% | 425.31K | $303.63K |
| 7 | Vanguard Fiduciary Trust Co | 0.38% | 296.68K | $211.80K |
| 8 | UBS Group AG | 0.25% | 190.84K | $136.24K |
| 9 | Arcus Capital Partners, Llc | 0.24% | 187.57K | $133.91K |
| 10 | ExodusPoint Capital Management, LP | 0.24% | 182.35K | $130.18K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COCH
A hearing company developing fully implanted devices will present in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOeGtZdXozWjVPbUpTV2ZaRmFlOTB5TzdTV3BQQ0lPUVpHU0N2dFcxdmNKXzBLNUR3SVl4RkhWU3MwRTB2cTNtSlNnOHY5YmxWRWxmdUVxYi00Sm1KdXVXQzJ5SXdpcDhHSU02SDdmNEtXN2FMVDZ3WU9raVQ5ZGUwRXVVREdWcnNCSGNBZ0…
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNdkpmN3lsOE85TWtwTno5TjVVS3pNRVRNNTdUelRtNmptcmNKS2Nob3pUcFJEV1hVSmhZNmJnM3ktZkJtVExhUWdpQXlXSWFJeGMyczh2RnIxdnpkWW82aml3NTdqZnRqalljTk9PXzl4ZW9kYmhZRVE1N1FLRFVMdko1NVVNbUNFZ0JacH…
COCH - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBaTUVHdE9teEV0ZG53cl83X1hYMU13M3JNQlZjaFRVRmluNWI0Q2NwNW1ONUwyajFmTEk4b1RIUUdsWm1wUEE?oc=5" target="_blank">COCH</a> <font color="#6f6f6f">Finviz</font>…
COCH Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5QNkoyX2gwdTJKOFBGNVV4VWoya0dkQnY3S3VOUzZvc09JTlNXZTFHSVpIMWNzbVhya1lySmZGeDBFS1N5Sm9MczlnMEo5UmZxXzhKYmJsQlpUWVhOV0dNZkNKYnBjc0o5Sjlma1pJdW1WWlVINHFBQW9n?oc=5" target="_blank">COC…
Envoy Medical Inc. (NASDAQ: COCH) Share Price, COCH Stock News, COCH Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xQ3FFcER5c3hYaXBtaWpBS1RKZkFJWTVkOEpNeE5rRGJ0ZTJFblE2SUFBMnMxeGl5dnJXUWwwUnlPZmFhMUVvWXd3azNiOXU0?oc=5" target="_blank">Envoy Medical Inc. (NASDAQ: COCH) Share Price, COCH Stock N…
Insiders Of Envoy Medical Are Up 98% On Their US$8.17m Purchase - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOVjRqb2J1NjdiaVdZUld4TXM5Yl8wd0pHQS1HTkVfZFN5QkdFRXg4MGg5RktSazI4eVZ6cElhVmhuVHBfb284NWdLc2djQkhCMDZmbUx1ZUFJUmF2R2NnVEk3V01NWVV5ZE1FeGtZYVQtdEtLOS1FMkZTRWIwSnJxZTdSZVVJSXRtdGJHb0…
COCH — Frequently Asked Questions
What is the current share price of Envoy Medical, Inc. (COCH)?
As of 2026-09-19 21:16 PDT, Envoy Medical, Inc. (COCH) trades at $0.71 on NasdaqCM. Its 52-week range is $0.39 to $1.59.
What is the market capitalisation of COCH?
Envoy Medical, Inc. (COCH) has a market capitalisation of $54.81M on NasdaqCM.
What is the P/E ratio of COCH?
COCH trades at a trailing price-to-earnings (P/E) ratio of -0.93. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 14.38.
Is COCH a good stock to buy?
This page provides a data-driven analysis of Envoy Medical, Inc. (COCH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.